Dec 18 (Reuters) - Biopharmaceutical company Avigen Inc said it sold all rights to its early-stage blood coagulation compound for $7 million to Baxter Healthcare Corp , boosting its shares 64 percent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results